Open in Screener

RNA

Avidity Biosciences Inc

Aug 08 • 04:00PM ET

46.29

Dollar change -1.23
Percentage change -2.59	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA VRTX SRPT ALNY IONS ARWR NBIX BLUE EXEL SGMO

| Held by: IWM VTI XBI VXF IWO VB IBB SCHA VBR VTWO

Index	RUT	P/E	-	EPS (ttm)	-3.56	Insider Own	8.98%	Shs Outstand	120.78M	Perf Week	28.87%
Market Cap	5.96B	Forward P/E	-	EPS next Y	-4.78	Insider Trans	-4.54%	Shs Float	117.11M	Perf Month	47.09%
Enterprise Value	4.78B	PEG	-	EPS next Q	-1.13	Inst Own	108.20%	Short Float	13.88%	Perf Quarter	61.35%
Income	-455.74M	P/S	555.02	EPS this Y	-49.56%	Inst Trans	6.36%	Short Ratio	7.47	Perf Half Y	31.84%
Sales	10.73M	P/B	4.69	EPS next Y	-10.48%	ROA	-33.56%	Short Interest	16.26M	Perf YTD	59.18%
Book/sh	9.87	P/C	5.03	EPS next 5Y	-6.27%	ROE	-37.76%	52W High	56.00 -17.34%	Perf Year	5.66%
Cash/sh	9.20	P/FCF	-	EPS past 3/5Y	-0.47% -34.37%	ROIC	-38.17%	52W Low	21.51 115.20%	Perf 3Y	165.27%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	5.33% 36.27%	Gross Margin	71.60%	Volatility	11.50% 7.34%	Perf 5Y	65.50%
Dividend TTM	-	EV/Sales	445.23	EPS Y/Y TTM	-20.45%	Oper. Margin	-4863.30%	ATR (14)	2.71	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	9.26	Sales Y/Y TTM	1.23%	Profit Margin	-4247.77%	RSI (14)	74.46	Recom	1.11
Dividend Gr. 3/5Y	- -	Current Ratio	9.26	EPS Q/Q	-83.30%	SMA20	25.92%	Beta	0.95	Target Price	67.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	88.12%	SMA50	38.88%	Rel Volume	2.26	Prev Close	47.52
Employees	391	LT Debt/Eq	0.00	Earnings	Aug 07 AMC	SMA200	38.02%	Avg Volume	2.18M	Price	46.29
IPO	Jun 12, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-26.28% 158.15%	Trades		Volume	4,919,992	Change	-2.59%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-25	Resumed	Goldman	Buy	$55
Jun-24-25	Initiated	Bernstein	Outperform	$50
Jun-17-25	Initiated	Wolfe Research	Outperform	$55
Jun-11-25	Initiated	Raymond James	Strong Buy	$65
Mar-13-25	Initiated	Citigroup	Buy	$70
Mar-12-25	Initiated	BMO Capital Markets	Outperform	$72
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$70
Dec-20-24	Initiated	H.C. Wainwright	Buy	$72
Nov-26-24	Initiated	RBC Capital Mkts	Outperform	$67
Sep-24-24	Initiated	Goldman	Buy	$59
Aug-28-24	Initiated	Barclays	Overweight	$63
May-03-24	Initiated	BofA Securities	Buy	$40
Mar-14-24	Initiated	Cantor Fitzgerald	Overweight	$60
May-22-23	Upgrade	Evercore ISI	In-line → Outperform	$20
Mar-31-23	Downgrade	Evercore ISI	Outperform → In-line	$20
Jul-20-22	Initiated	Chardan Capital Markets	Buy	$29
Jul-12-22	Initiated	Raymond James	Strong Buy	$29
Sep-07-21	Initiated	Evercore ISI	Outperform	$50
Jun-17-21	Initiated	Needham	Buy	$50
Apr-26-21	Resumed	Credit Suisse	Outperform	$37

Show Previous Ratings

Aug-07-25 05:10PM	Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights (PR Newswire)
10:19AM	Avidity (RNA) Gets 26% Jump on Potential Takeover (Insider Monkey)
Aug-06-25 05:10PM	Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +26.14%
12:47PM	Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal (Investor's Business Daily)
12:00PM	Loading…
12:00PM	Avidity Biosciences stock soars on Novartis takeover approach report (Investing.com)
11:41AM	Novartis weighs deal for biotech Avidity Biosciences, FT reports (Reuters)
Jul-28-25 09:39AM	Facioscapulohumeral Muscular Dystrophy Pipeline Market Insight Report 2025 \| In-depth Analysis of 10+ Companies and 12+ Pipeline Drugs (GlobeNewswire)
09:00AM	Avidity Biosciences Announces Completion of Enrollment for HARBOR, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission (PR Newswire)
Jul-26-25 11:03AM	Avidity (RNA) Jumps 9.2% on Drug Candidate's Breakthrough Therapy Designation (Insider Monkey)
Jul-23-25 09:00AM	Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping (PR Newswire)
Jul-13-25 06:15AM	Raymond James Predicts Up to ~760% Surge for These 2 Strong Buy Stocks (TipRanks)
Jun-11-25 08:03PM	Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James (Insider Monkey)
09:45AM	Raymond James bullish on biotech firms on favorable valuation (Investing.com)
09:00AM	Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress (PR Newswire)
09:25AM	Loading…
Jun-10-25 09:25AM	Avidity Biosciences price target raised to $75 from $65 at Chardan (TipRanks)
Jun-09-25 02:04PM	Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial (Benzinga) -9.88%
07:01AM	Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants (PR Newswire)
07:00AM	Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD Study in FSHD (PR Newswire)
May-21-25 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-08-25 05:55PM	Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +9.63%
04:05PM	Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights (PR Newswire)
May-06-25 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire) -18.65%
Apr-24-25 05:15PM	Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates (Zacks)
Apr-22-25 05:30AM	Trumps FDA Sends a Bullish Signal to Biotech (The Wall Street Journal)
Apr-21-25 04:09PM	Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost (Investor's Business Daily) +6.98%
04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-08-25 09:00AM	Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 (PR Newswire) -5.49%
Apr-05-25 05:22PM	Avidity Biosciences (RNA): Among Unstoppable Stocks That Could Double Your Money (Insider Monkey)
Apr-03-25 09:34AM	Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? (Zacks) -5.61%
11:50AM	Loading…
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -9.42%
09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
Mar-31-25 09:00AM	Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy (PR Newswire) -6.58%
Mar-28-25 09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
Mar-26-25 10:17AM	The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (SeekingAlpha)
Mar-21-25 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +7.98%
Mar-17-25 07:00AM	Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44 Trial (PR Newswire) +8.74%
Mar-12-25 04:05PM	Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (PR Newswire) +10.24%
Feb-28-25 09:00AM	Avidity Biosciences Honors Rare Disease Day and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases (PR Newswire) +5.36%
Feb-27-25 05:40PM	Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights (PR Newswire)
Feb-25-25 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-21-25 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jan-20-25 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jan-17-25 11:06AM	Avidity Biosciences, Inc. (RNA): The Biotech Stock with Biggest Upside Potential (Insider Monkey)
Jan-08-25 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
09:00AM	Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 (PR Newswire)
Jan-01-25 01:12PM	Why Is Avidity Biosciences, Inc. (RNA) Among the Best Multibagger Stocks to Buy Right Now? (Insider Monkey)
Dec-20-24 05:00PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-26-24 10:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
Nov-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-13-24 04:07PM	Avidity Bio Has Surged 416% This Year And That's Before Today's 'Game-Changing' News (Investor's Business Daily) +12.35%
Nov-12-24 07:00AM	Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations (PR Newswire)
Nov-07-24 06:10PM	Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights (PR Newswire)
Nov-06-24 10:00AM	Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for (Zacks)
04:27AM	An RNAi renaissance is creating a new generation of startups (BioPharma Dive)
Oct-31-24 09:00AM	Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024 (PR Newswire)
Oct-30-24 08:00AM	Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy (PR Newswire)
Oct-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -7.41%
Oct-18-24 08:00AM	Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up (Investor's Business Daily)
Oct-04-24 07:00PM	Why Avidity Biosciences Zoomed to a 12% Gain This Week (Motley Fool) -7.08%
10:53AM	FDA lifts clinical hold on Aviditys lead antibody conjugate therapy trial (Pharmaceutical Technology)
Oct-03-24 07:00AM	Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001) (PR Newswire)
Sep-29-24 06:27AM	Is Avidity Biosciences, Inc. (RNA) the Best Performing Long Term Stock in 2024? (Insider Monkey)
Sep-26-24 07:34PM	Is Avidity Biosciences Inc. (RNA) the Best Performing Small-Cap Stock in 2024? (Insider Monkey) -8.23%
Sep-25-24 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
Sep-23-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Sep-05-24 09:00AM	Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month (PR Newswire)
Aug-28-24 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Aug-20-24 07:44AM	Avidity, Kymera raise fresh funds; Walgreens partners with BARDA (BioPharma Dive)
Aug-19-24 09:00AM	Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Aug-14-24 08:30PM	Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock (PR Newswire) +6.16%
Aug-13-24 04:01PM	Avidity Biosciences Announces Proposed Public Offering of Common Stock (PR Newswire)
Aug-09-24 08:53PM	RNA Stock Earnings: Avidity Biosciences Beats EPS, Misses Revenue for Q2 2024 (InvestorPlace) +12.13% -5.26%
05:20PM	Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:17PM	How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics (Investor's Business Daily)
04:05PM	Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights (PR Newswire)
07:00AM	Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in the Phase 1/2 EXPLORE44 Trial (PR Newswire)
Aug-05-24 09:15AM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
09:00AM	Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer (PR Newswire)
Jul-24-24 06:41AM	3 Stocks Doing Even Better Than Superstar Super Micro (SMCI) (InvestorPlace)
Jul-23-24 07:00AM	3 Russell 2000 Growth Stocks That Could Be Worth the Risk (Motley Fool)
Jul-22-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jul-03-24 06:53AM	Aviditys FSHD drug del-brax shows promise in Phase I/II trial (Clinical Trials Arena)
Jun-24-24 04:05PM	Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors (Business Wire)
Jun-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-20-24 09:00AM	Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day (PR Newswire)
Jun-17-24 04:05PM	Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Jun-14-24 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
Jun-13-24 08:00PM	Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock (PR Newswire)
10:39AM	Avidity (RNA) Up 33% on Rare Muscle Disease Study Results (Zacks)
Jun-12-24 04:04PM	The 'Impressive' Results That Sent Top 1% Avidity Biosciences To A Record (Investor's Business Daily) +32.64%
04:01PM	Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock (PR Newswire)
07:45AM	Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss (BioPharma Dive)
07:00AM	Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People Living with Facioscapulohumeral Muscular Dystrophy (PR Newswire)
May-29-24 04:05PM	Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress (PR Newswire)
08:45AM	2 Potentially High-Reward Growth Stocks to Buy Right Now (Motley Fool)
May-23-24 06:00AM	Dip Then Rip? 3 Nasdaq Stocks to Buy Before the Rebound (InvestorPlace) -7.26%

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mosbrooker Eric	Chief Commercial Officer	Aug 06 '25	Option Exercise	9.05	124,687	1,128,417	185,807	Aug 08 05:45 PM
Mosbrooker Eric	Chief Commercial Officer	Aug 06 '25	Sale	44.06	130,807	5,763,697	55,000	Aug 08 05:45 PM
WILSON TROY EDWARD	Director	Aug 06 '25	Option Exercise	12.14	29,500	358,260	91,425	Aug 08 05:42 PM
WILSON TROY EDWARD	Director	Aug 06 '25	Sale	45.00	65,554	2,949,930	17,776	Aug 08 05:42 PM
WILSON TROY EDWARD	Director	Aug 06 '25	Sale	45.00	29,500	1,327,500	69,425	Aug 08 05:42 PM
LEVIN ARTHUR A	Director	Aug 06 '25	Option Exercise	22.34	107,500	2,401,550	127,150	Aug 08 05:41 PM
LEVIN ARTHUR A	Director	Aug 06 '25	Sale	47.62	107,500	5,118,881	19,650	Aug 08 05:41 PM
Hughes Steven George	Chief Medical Officer	Aug 06 '25	Option Exercise	12.21	47,451	579,180	90,517	Aug 08 05:39 PM
Hughes Steven George	Chief Medical Officer	Aug 06 '25	Sale	42.74	81,434	3,480,269	38,867	Aug 08 05:39 PM
ERIC MOSBROOKER	Officer	Aug 06 '25	Proposed Sale	38.26	130,807	5,004,676		Aug 06 04:23 PM
STEVEN GEORGE HUGHES	Officer	Aug 06 '25	Proposed Sale	38.26	81,434	3,115,665		Aug 06 04:23 PM
ARTHUR LEVIN	Director	Aug 06 '25	Proposed Sale	38.26	107,500	4,112,950		Aug 06 04:23 PM
MICHAEL MACLEAN	Officer	Aug 06 '25	Proposed Sale	38.26	30,914	1,182,770		Aug 06 04:22 PM
WILSON TROY EDWARD	Chairman	Aug 06 '25	Proposed Sale	45.00	95,054	4,277,430		Aug 06 04:08 PM
Moriarty John B	Chief Legal Officer	Aug 04 '25	Sale	36.21	2,245	81,291	47,755	Aug 05 05:27 PM
Gallagher Kathleen P.	Chief Program Officer	Jun 17 '25	Sale	30.24	911	27,549	50,392	Jun 18 06:02 PM
KATHLEEN GALLAGHER	Officer	Jun 17 '25	Proposed Sale	29.80	911	27,148		Jun 17 04:19 PM
Flanagan W. Michael	Chief Scientific Officer	Jun 11 '25	Option Exercise	14.22	20,000	284,400	100,195	Jun 12 06:18 PM
Flanagan W. Michael	Chief Scientific Officer	Jun 11 '25	Sale	32.88	20,000	657,694	80,195	Jun 12 06:18 PM
WILLIAM MICHAEL FLANAGAN	Officer	Jun 11 '25	Proposed Sale	33.62	20,000	672,400		Jun 11 04:31 PM
Gallagher Kathleen P.	Chief Program Officer	Jun 02 '25	Option Exercise	16.65	5,875	97,819	56,429	Jun 04 04:48 PM
Gallagher Kathleen P.	Chief Program Officer	Jun 02 '25	Sale	32.48	5,875	190,833	50,554	Jun 04 04:48 PM
KATHLEEN GALLAGHER	Officer	Jun 02 '25	Proposed Sale	30.98	5,875	182,008		Jun 02 04:37 PM
Gallagher Kathleen P.	Chief Program Officer	May 01 '25	Option Exercise	16.65	5,875	97,819	56,429	May 02 07:55 PM
Gallagher Kathleen P.	Chief Program Officer	May 01 '25	Sale	32.40	5,875	190,324	50,554	May 02 07:55 PM
KATHLEEN GALLAGHER	Officer	May 01 '25	Proposed Sale	32.65	5,875	191,819		May 01 04:57 PM
Gallagher Kathleen P.	Chief Program Officer	Apr 01 '25	Option Exercise	14.81	5,875	87,004	56,100	Apr 03 04:56 PM
Gallagher Kathleen P.	Chief Program Officer	Apr 01 '25	Sale	27.83	5,875	163,486	50,554	Apr 03 04:56 PM
Hughes Steven George	Chief Medical Officer	Mar 20 '25	Sale	31.06	9,578	297,491	72,850	Mar 21 06:44 PM
Boyce Sarah	President and CEO	Mar 20 '25	Sale	31.06	31,540	979,563	305,871	Mar 21 06:42 PM
Flanagan W. Michael	Chief Scientific Officer	Mar 20 '25	Sale	31.06	11,780	365,868	80,195	Mar 21 06:40 PM
MacLean Michael F	Chief Financial Officer	Mar 20 '25	Sale	31.06	7,935	246,425	96,720	Mar 21 06:38 PM
McCarthy Teresa	Chief Human Resources Officer	Mar 20 '25	Sale	31.06	7,778	241,583	97,130	Mar 21 06:36 PM
Flanagan W. Michael	Chief Scientific Officer	Mar 11 '25	Option Exercise	14.22	20,000	284,400	111,975	Mar 12 04:23 PM
Flanagan W. Michael	Chief Scientific Officer	Mar 11 '25	Sale	30.13	20,000	602,614	91,975	Mar 12 04:23 PM
WILLIAM MICHAEL FLANAGAN	Officer	Mar 11 '25	Proposed Sale	30.04	20,000	600,800		Mar 11 04:35 PM
Gallagher Kathleen P.	Chief Program Officer	Mar 03 '25	Option Exercise	14.70	5,875	86,362	56,429	Mar 04 06:17 PM
Gallagher Kathleen P.	Chief Program Officer	Mar 03 '25	Sale	29.41	5,875	172,807	50,554	Mar 04 06:17 PM
Gallagher Kathleen P.	Chief Program Officer	Feb 03 '25	Option Exercise	16.65	5,875	97,819	56,429	Feb 05 05:01 PM
Gallagher Kathleen P.	Chief Program Officer	Feb 03 '25	Sale	32.16	5,875	188,918	50,554	Feb 05 05:01 PM
KATHLEEN GALLAGHER	Officer	Feb 03 '25	Proposed Sale	32.93	17,625	580,391		Feb 03 04:34 PM
LEVIN ARTHUR A	Director	Jan 21 '25	Sale	28.60	1,872	53,537	12,958	Jan 23 08:17 PM
MacLean Michael F	Chief Financial Officer	Jan 21 '25	Sale	28.59	3,287	93,985	104,655	Jan 23 08:15 PM
McCarthy Teresa	Chief Human Resources Officer	Jan 21 '25	Sale	28.59	2,959	84,612	104,908	Jan 23 08:14 PM
Flanagan W. Michael	Chief Scientific Officer	Jan 21 '25	Sale	28.60	5,672	162,192	91,975	Jan 23 08:12 PM
Boyce Sarah	President and CEO	Jan 21 '25	Sale	28.59	10,397	297,291	337,411	Jan 23 08:10 PM
Gallagher Kathleen P.	Chief Program Officer	Jan 22 '25	Sale	30.16	5,629	169,776	50,554	Jan 23 08:08 PM
Gallagher Kathleen P.	Chief Program Officer	Jan 21 '25	Sale	28.59	3,782	108,136	56,183	Jan 23 08:08 PM
Hughes Steven George	Chief Medical Officer	Jan 21 '25	Sale	28.59	3,947	112,856	82,428	Jan 23 08:06 PM
KATHLEEN GALLAGHER	Officer	Jan 22 '25	Proposed Sale	30.84	6,924	213,536		Jan 22 04:25 PM
Flanagan W. Michael	CSTO	Dec 18 '24	Sale	32.66	12,742	416,154	72,647	Dec 19 06:17 PM
MacLean Michael F	Chief Financial Officer	Dec 18 '24	Sale	32.66	11,151	364,192	82,942	Dec 19 06:16 PM
Boyce Sarah	President and CEO	Dec 18 '24	Sale	32.66	31,855	1,040,384	265,308	Dec 19 06:15 PM
McCarthy Teresa	Chief Human Resources Officer	Dec 18 '24	Sale	32.66	11,151	364,192	82,867	Dec 19 06:15 PM
McCarthy Teresa	Chief Human Resources Officer	Dec 16 '24	Option Exercise	14.22	25,000	355,500	119,018	Dec 18 04:46 PM
McCarthy Teresa	Chief Human Resources Officer	Dec 16 '24	Sale	33.26	25,000	831,605	94,018	Dec 18 04:46 PM
TERESA MCCARTHY	Officer	Dec 16 '24	Proposed Sale	32.49	25,000	812,250		Dec 16 04:29 PM
Flanagan W. Michael	CSTO	Dec 11 '24	Option Exercise	22.47	24,000	539,280	109,389	Dec 13 06:08 PM
Flanagan W. Michael	CSTO	Dec 11 '24	Sale	35.77	24,000	858,401	85,389	Dec 13 06:08 PM
W. MICHAEL FLANAGAN	Officer	Dec 11 '24	Proposed Sale	36.10	24,000	866,400		Dec 11 04:59 PM
McCarthy Teresa	Chief Human Resources Officer	Nov 18 '24	Option Exercise	14.22	25,000	355,500	119,018	Nov 20 06:10 PM
McCarthy Teresa	Chief Human Resources Officer	Nov 18 '24	Sale	41.14	25,000	1,028,520	94,018	Nov 20 06:10 PM
LEVIN ARTHUR A	Director	Nov 19 '24	Option Exercise	1.24	3,323	4,121	18,153	Nov 20 06:06 PM
LEVIN ARTHUR A	Director	Nov 19 '24	Sale	42.12	3,323	139,973	14,830	Nov 20 06:06 PM
MacLean Michael F	Chief Financial Officer	Nov 06 '24	Option Exercise	8.43	79,057	666,064	159,275	Nov 08 04:50 PM
MacLean Michael F	Chief Financial Officer	Nov 06 '24	Sale	45.56	106,319	4,843,979	94,093	Nov 08 04:50 PM
MICHAEL MACLEAN	Officer	Nov 06 '24	Proposed Sale	45.09	106,319	4,793,924		Nov 06 04:56 PM
LEVIN ARTHUR A	Director	Oct 21 '24	Option Exercise	1.24	5,000	6,200	19,830	Oct 23 04:19 PM
LEVIN ARTHUR A	Director	Oct 21 '24	Sale	46.63	5,000	233,168	14,830	Oct 23 04:19 PM
ARTHUR A LEVIN	Director	Oct 21 '24	Proposed Sale	50.45	8,323	419,895		Oct 21 04:21 PM
McCarthy Teresa	Chief Human Resources Officer	Oct 16 '24	Option Exercise	14.22	25,000	355,500	119,018	Oct 17 04:20 PM
McCarthy Teresa	Chief Human Resources Officer	Oct 16 '24	Sale	48.52	25,000	1,213,010	94,018	Oct 17 04:20 PM
LEVIN ARTHUR A	Officer	Oct 16 '24	Proposed Sale	46.60	22,500	1,048,500		Oct 16 01:48 PM
Thompson Tamar	Director	Oct 07 '24	Option Exercise	27.63	30,000	828,900	30,000	Oct 09 05:23 PM
Thompson Tamar	Director	Oct 07 '24	Sale	44.98	30,000	1,349,259	0	Oct 09 05:23 PM
Thompson Tamar	Officer	Oct 07 '24	Proposed Sale	47.30	30,000	1,419,000		Oct 07 04:39 PM
Flanagan W. Michael	CSTO	Oct 01 '24	Option Exercise	26.75	62,500	1,671,875	147,889	Oct 03 04:09 PM
Flanagan W. Michael	CSTO	Oct 01 '24	Sale	47.62	62,500	2,976,112	85,389	Oct 03 04:09 PM
WILLIAM MICHAEL FLANAGAN	Officer	Oct 01 '24	Proposed Sale	45.93	38,018	1,746,167		Oct 01 04:36 PM
McCarthy Teresa	Chief Human Resources Officer	Sep 23 '24	Sale	44.00	13,153	578,737	69,018	Sep 23 09:06 PM
Flanagan W. Michael	CSTO	Sep 23 '24	Sale	43.95	25,000	1,098,733	72,718	Sep 23 09:03 PM
Boyce Sarah	President and CEO	Sep 23 '24	Sale	44.00	32,880	1,446,723	234,663	Sep 23 09:01 PM
MacLean Michael F	Chief Financial Officer	Sep 23 '24	Sale	44.00	11,510	506,440	96,355	Sep 23 08:59 PM
WILLIAM MICHAEL FLANAGAN	Officer	Sep 23 '24	Proposed Sale	44.48	36,329	1,615,914		Sep 23 04:27 PM
LEVIN ARTHUR A	Director	Sep 19 '24	Option Exercise	1.24	5,000	6,200	19,830	Sep 20 05:19 PM
LEVIN ARTHUR A	Director	Sep 19 '24	Sale	45.73	5,000	228,658	14,830	Sep 20 05:19 PM
Flanagan W. Michael	CSTO	Sep 11 '24	Option Exercise	25.24	96,500	2,435,855	138,265	Sep 13 04:25 PM
Flanagan W. Michael	CSTO	Sep 11 '24	Sale	40.40	111,394	4,500,244	60,871	Sep 13 04:25 PM
McCarthy Teresa	Chief Human Resources Officer	Sep 11 '24	Option Exercise	14.22	25,000	355,500	82,171	Sep 13 04:17 PM
McCarthy Teresa	Chief Human Resources Officer	Sep 11 '24	Sale	40.40	25,000	1,010,042	57,171	Sep 13 04:17 PM
WILLIAM MICHAEL FLANAGAN	Officer	Sep 11 '24	Proposed Sale	40.79	111,394	4,543,761		Sep 11 04:18 PM
TERESA MCCARTHY	Officer	Sep 11 '24	Proposed Sale	40.79	75,000	3,059,250		Sep 11 04:18 PM
LEVIN ARTHUR A	Director	Aug 19 '24	Option Exercise	1.24	5,000	6,200	19,830	Aug 21 04:30 PM
LEVIN ARTHUR A	Director	Aug 19 '24	Sale	45.19	5,000	225,946	14,830	Aug 21 04:30 PM

Open in Screener

PBYI

Puma Biotechnology Inc

Aug 08 • 04:00PM ET

3.69

Dollar change +0.40
Percentage change 12.16	%

Healthcare • Biotechnology • USA • NASD

PBYI Puma Biotechnology Inc daily Stock Chart

Peers: INCY MRNA EXEL SRPT BPMC FGEN NKTR KPTI LGND AFMD

| Held by: VTI AVUV IWM VXF JSMD JSML IWN VTWO DFAS BSVO

Index	RUT	P/E	3.76	EPS (ttm)	0.98	Insider Own	24.71%	Shs Outstand	49.89M	Perf Week	20.20%
Market Cap	185.87M	Forward P/E	11.42	EPS next Y	0.32	Insider Trans	-1.45%	Shs Float	37.93M	Perf Month	4.83%
Enterprise Value	136.99M	PEG	-	EPS next Q	0.04	Inst Own	54.05%	Short Float	6.87%	Perf Quarter	20.20%
Income	48.45M	P/S	0.78	EPS this Y	-20.24%	Inst Trans	5.07%	Short Ratio	7.18	Perf Half Y	27.68%
Sales	238.06M	P/B	1.76	EPS next Y	-34.68%	ROA	24.23%	Short Interest	2.61M	Perf YTD	20.98%
Book/sh	2.10	P/C	1.89	EPS next 5Y	-18.96%	ROE	63.24%	52W High	4.06 -9.11%	Perf Year	-8.44%
Cash/sh	1.95	P/FCF	4.20	EPS past 3/5Y	- -	ROIC	41.92%	52W Low	2.22 65.84%	Perf 3Y	18.65%
Dividend Est.	-	EV/EBITDA	2.39	Sales past 3/5Y	-3.08% -3.28%	Gross Margin	72.33%	Volatility	8.66% 4.95%	Perf 5Y	-66.12%
Dividend TTM	-	EV/Sales	0.58	EPS Y/Y TTM	137.93%	Oper. Margin	19.35%	ATR (14)	0.18	Perf 10Y	-95.93%
Dividend Ex-Date	-	Quick Ratio	1.62	Sales Y/Y TTM	8.63%	Profit Margin	20.35%	RSI (14)	65.89	Recom	4.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.73	EPS Q/Q	224.52%	SMA20	10.79%	Beta	1.32	Target Price	3.00
Payout	0.00%	Debt/Eq	0.47	Sales Q/Q	11.37%	SMA50	8.28%	Rel Volume	3.72	Prev Close	3.29
Employees	172	LT Debt/Eq	0.10	Earnings	Aug 07 AMC	SMA200	17.36%	Avg Volume	363.08K	Price	3.69
IPO	Apr 20, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	41.18% -5.38%	Trades		Volume	1,349,303	Change	12.16%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-28-21	Upgrade	Citigroup	Neutral → Buy	$11
Jun-25-20	Resumed	BofA/Merrill	Underperform	$9
Oct-08-19	Downgrade	Goldman	Neutral → Sell	$24 → $8
May-10-19	Downgrade	Citigroup	Buy → Neutral	$24
May-10-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$57 → $20
Jan-17-19	Initiated	Leerink Partners	Mkt Perform	$21
Jan-03-19	Downgrade	Guggenheim	Buy → Neutral
Nov-19-18	Upgrade	Goldman	Sell → Neutral
Nov-02-18	Downgrade	JP Morgan	Neutral → Underweight
Nov-02-18	Downgrade	BofA/Merrill	Buy → Underperform
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight	$75
Sep-17-18	Initiated	Goldman	Sell	$42
May-11-18	Reiterated	Stifel	Buy	$95 → $87
Nov-10-17	Reiterated	RBC Capital Mkts	Sector Perform	$92 → $108
Nov-10-17	Reiterated	Citigroup	Buy	$156 → $164
Oct-02-17	Reiterated	Stifel	Buy	$110 → $130
Sep-11-17	Reiterated	Credit Suisse	Outperform	$118 → $136
Jul-10-17	Resumed	Leerink Partners	Outperform	$115
Jun-06-17	Reiterated	RBC Capital Mkts	Sector Perform	$60 → $88
May-25-17	Reiterated	RBC Capital Mkts	Sector Perform	$40 → $60

Show Previous Ratings

Aug-08-25 05:00PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +12.16%
10:26AM	PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues (Zacks)
Aug-07-25 05:55PM	Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
04:56PM	Puma Biotech: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports Second Quarter Financial Results (Business Wire)
06:05PM	Loading…
Aug-06-25 06:05PM	Adma Biologics (ADMA) Q2 Earnings and Revenues Beat Estimates (Zacks)
Jul-24-25 04:15PM	Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results (Business Wire)
Jul-15-25 08:31AM	Add These 4 Top-Ranked Liquid Stocks to Boost Portfolio Returns (Zacks)
Jul-14-25 09:40AM	Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now? (Zacks)
Jul-10-25 08:50AM	Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors (Zacks)
Jul-08-25 10:31AM	Bayer Begins Phase I/II Study on Cell Therapy for Eye Disease (Zacks)
Jul-04-25 08:35AM	AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer (Zacks)
Jul-02-25 05:03PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:34AM	Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek (Zacks)
Jul-01-25 11:55AM	RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance (Zacks)
10:05AM	Loading…
10:05AM	ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B (Zacks)
Jun-30-25 10:40AM	Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why (Zacks)
Jun-27-25 10:58AM	PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal (Zacks)
09:40AM	Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? (Zacks)
Jun-25-25 11:30AM	NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study (Zacks)
Jun-24-25 08:50AM	Fast-paced Momentum Stock Puma Biotech (PBYI) Is Still Trading at a Bargain (Zacks)
Jun-19-25 11:11AM	Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma (Zacks)
Jun-18-25 10:51AM	Bayer Seeks FDA Approval for MRI Contrast Agent Gadoquatrane (Zacks)
Jun-12-25 11:30AM	Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report? (Zacks)
Jun-11-25 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
Jun-04-25 05:33PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.39%
May-28-25 08:50AM	Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors (Zacks)
May-26-25 09:40AM	Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now? (Zacks)
May-12-25 08:50AM	Despite Fast-paced Momentum, Puma Biotech (PBYI) Is Still a Bargain Stock (Zacks)
May-09-25 09:40AM	Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? (Zacks) -5.21%
08:48AM	Loading…
08:48AM	PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates (Zacks)
03:39AM	Puma Biotechnology Inc (PBYI) Q1 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges (GuruFocus.com)
May-08-25 05:55PM	Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates (Zacks)
04:52PM	Puma Biotech: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports First Quarter Financial Results (Business Wire)
May-07-25 05:20PM	Puma Biotechnology Q1 2025 Earnings Preview (Seeking Alpha)
01:25PM	Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y (Zacks)
11:55AM	JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook (Zacks)
08:10AM	Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-06-25 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-05-25 09:15AM	ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue? (Zacks)
May-01-25 08:05AM	Biogen Inc. (BIIB) Q1 Earnings Lag Estimates (Zacks)
Apr-30-25 12:00PM	Puma Biotech (PBYI) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
06:00AM	Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX (neratinib) for Breast Cancer Patients (GlobeNewswire)
Apr-28-25 03:03PM	Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025 (Business Wire)
Apr-24-25 04:11PM	Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results (Business Wire)
Apr-23-25 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
Apr-21-25 09:13AM	Is the Options Market Predicting a Spike in Puma Biotechnology Stock? (Zacks)
Apr-11-25 01:20PM	Puma Biotechnology: Initiating Hold Rating With Limited Near-Term Upside And Uncertain Pipeline Potential (Seeking Alpha)
Apr-02-25 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-26-25 09:00AM	Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025 (Business Wire)
Mar-20-25 12:23PM	Puma Biotechnology Stock Rises 35% in 6 Months: Here's Why (Zacks)
Mar-18-25 04:35AM	Puma Biotechnology (PBYI): One of the Best Short-Term Stocks to Buy Right Now (Insider Monkey)
Mar-05-25 06:05PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
05:30PM	Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference (Business Wire)
Mar-03-25 09:40AM	Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now? (Zacks) -6.42%
Feb-28-25 12:04PM	Q4 2024 Puma Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents) +19.73%
02:34AM	Puma Biotechnology Inc (PBYI) Q4 2024 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
Feb-27-25 05:29PM	Puma Biotech: Q4 Earnings Snapshot (Associated Press Finance) +7.94%
04:05PM	Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-26-25 04:15PM	Puma Biotechnology to Present at TD Cowens 45th Annual Health Care Conference (Business Wire)
Feb-13-25 04:15PM	Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-05-25 05:05PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-03-25 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.45% +20.34%
Jan-01-25 09:40AM	Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? (Zacks)
Dec-23-24 09:01AM	Puma Biotechnologys NERLYNX Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation (Business Wire)
Dec-04-24 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-28-24 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
Nov-21-24 05:38AM	Puma commences Phase II trial of alisertib for breast cancer treatment (Clinical Trials Arena)
Nov-20-24 08:57AM	Puma Biotechnology Announces Initiation of ALISCA-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer (Business Wire)
Nov-08-24 02:27AM	Puma Biotechnology Inc (PBYI) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com)
Nov-07-24 05:33PM	Puma Biotech: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports Third Quarter 2024 Financial Results (Business Wire)
Nov-05-24 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-24-24 04:07PM	Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results (Business Wire) +5.36%
Sep-12-24 07:59AM	Transforming Cancer Therapy Stocks to Watch In The Oncology Sector (News Direct)
Sep-03-24 04:15PM	Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-21-24 05:00AM	The Future of Medicine: Key Biotech Stocks to Watch (News Direct)
Aug-06-24 05:23PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +12.26% -7.44%
Aug-02-24 10:07AM	Puma Biotechnology's (PBYI) Q2 Loss Narrower Than Expected (Zacks) +9.43%
Aug-01-24 05:04PM	Puma Biotech: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports Second Quarter Financial Results (Business Wire)
Jul-23-24 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
Jul-18-24 04:10PM	Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results (Business Wire)
Jul-02-24 05:30PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.49%
Jun-07-24 05:37PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-03-24 02:33PM	Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer (Business Wire)
Jun-02-24 10:01AM	Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041) (Business Wire)
May-28-24 09:00AM	Puma Biotechnology to Join Russell 3000 Index (Business Wire)
May-24-24 11:57AM	Puma Biotechnology (PBYI) Falls 38% in 3 Months: Here's Why (Zacks)
May-23-24 05:15PM	Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting (Business Wire) -5.67%
May-20-24 09:59AM	Implied Volatility Surging for Puma Biotechnology (PBYI) Stock Options (Zacks) +6.72%
May-03-24 01:09PM	Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:31AM	Puma Biotechnology's (PBYI) Q1 Earnings and Revenues Beat (Zacks)
04:02AM	Puma Biotechnology Inc (PBYI) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of ... (GuruFocus.com)
May-02-24 09:55PM	PBYI Stock Earnings: Puma Biotechnology Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:05PM	Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:48PM	Puma Biotechnology Inc (PBYI) Reports Q1 Financial Results, Misses Analyst Revenue and EPS Forecasts (GuruFocus.com)
05:12PM	Puma Biotech: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports First Quarter Financial Results (Business Wire)

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cesano Alessandra	Director	Jul 18 '25	Sale	3.37	27,000	90,909	41,850	Jul 22 07:51 PM
Cesano Alessandra	Director	Jul 18 '25	Proposed Sale	3.37	27,000	90,909		Jul 18 04:16 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jul 08 '25	Sale	3.53	5,587	19,739	208,164	Jul 10 08:56 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jul 09 '25	Sale	3.54	3,935	13,910	204,229	Jul 10 08:56 PM
HUNT DOUGLAS M	See Remarks	Jul 08 '25	Sale	3.53	4,374	15,453	168,337	Jul 10 08:52 PM
HUNT DOUGLAS M	See Remarks	Jul 09 '25	Sale	3.54	3,443	12,171	164,894	Jul 10 08:52 PM
AUERBACH ALAN H	President and CEO	Jul 08 '25	Sale	3.53	25,592	90,417	7,202,481	Jul 10 08:49 PM
AUERBACH ALAN H	President and CEO	Jul 09 '25	Sale	3.54	21,580	76,285	7,180,901	Jul 10 08:49 PM
NOUGUES MAXIMO F	Officer	Jul 09 '25	Proposed Sale	3.54	3,935	13,910		Jul 09 04:48 PM
AUERBACH ALAN H	Officer	Jul 09 '25	Proposed Sale	3.54	21,580	76,285		Jul 09 04:36 PM
HUNT DOUGLAS M	Officer	Jul 09 '25	Proposed Sale	3.54	3,443	12,171		Jul 09 04:27 PM
AUERBACH ALAN H	Officer	Jul 08 '25	Proposed Sale	3.53	25,592	90,424		Jul 08 04:41 PM
NOUGUES MAXIMO F	Officer	Jul 08 '25	Proposed Sale	3.53	5,587	19,741		Jul 08 04:39 PM
HUNT DOUGLAS M	Officer	Jul 08 '25	Proposed Sale	3.53	4,374	15,455		Jul 08 04:29 PM
WILSON TROY EDWARD	Director	Jun 13 '25	Sale	3.40	10,800	36,720	43,550	Jun 17 07:55 PM
Stuglik Brian M	Director	Jun 13 '25	Sale	3.39	8,100	27,459	94,958	Jun 17 07:52 PM
Senderowicz Adrian	Director	Jun 13 '25	Sale	3.40	27,000	91,800	27,000	Jun 17 07:49 PM
MOYES JAY M	Director	Jun 13 '25	Sale	3.40	22,000	74,800	53,322	Jun 17 07:46 PM
Dorval Allison	Director	Jun 13 '25	Sale	3.40	11,610	39,474	75,390	Jun 17 07:43 PM
Cesano Alessandra	Director	Jun 13 '25	Sale	3.40	12,150	41,310	68,850	Jun 17 07:41 PM
WILSON TROY EDWARD	Director	Jun 13 '25	Proposed Sale	3.40	10,800	36,678		Jun 13 04:15 PM
Senderowicz Adrian	Director	Jun 13 '25	Proposed Sale	3.40	27,000	91,767		Jun 13 04:11 PM
Dorval Allison	Director	Jun 13 '25	Proposed Sale	3.40	11,610	39,437		Jun 13 04:10 PM
Cesano Alessandra	Director	Jun 13 '25	Proposed Sale	3.40	12,150	41,285		Jun 13 04:09 PM
Stuglik Brian M	Director	Jun 13 '25	Proposed Sale	3.39	8,100	27,497		Jun 13 04:07 PM
MOYES JAY M	Director	Jun 13 '25	Proposed Sale	3.40	22,000	74,756		Jun 13 04:04 PM
Ludwig Jeffrey Jerome	Former Officer	May 21 '25	Proposed Sale	3.42	55,882	191,310		May 21 03:00 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jan 02 '25	Sale	3.15	10,227	32,232	152,295	Jan 03 07:33 PM
Ludwig Jeffrey Jerome	Chief Commercial Officer	Jan 02 '25	Sale	3.15	9,437	29,743	108,951	Jan 03 07:31 PM
HUNT DOUGLAS M	See Remarks	Jan 02 '25	Sale	3.15	8,633	27,209	124,594	Jan 03 07:28 PM
AUERBACH ALAN H	President and CEO	Jan 02 '25	Sale	3.15	33,841	106,657	7,029,674	Jan 03 07:12 PM
NOUGUES MAXIMO F	Officer	Jan 02 '25	Proposed Sale	3.05	10,227	31,192		Jan 02 08:37 PM
Ludwig Jeffrey Jerome	Officer	Jan 02 '25	Proposed Sale	3.05	9,437	28,783		Jan 02 08:34 PM
HUNT DOUGLAS M	Officer	Jan 02 '25	Proposed Sale	3.05	8,633	26,331		Jan 02 08:33 PM
AUERBACH ALAN H	Officer	Jan 02 '25	Proposed Sale	3.05	33,841	103,215		Jan 02 08:30 PM
MILLER MICHAEL PATRICK	Director	Aug 12 '24	Sale	3.49	23,358	81,466	47,000	Aug 13 09:09 PM
MILLER MICHAEL PATRICK	Director	Aug 12 '24	Proposed Sale	3.76	23,358	87,826		Aug 12 09:27 PM

Open in Screener

KURA

Kura Oncology Inc

Aug 08 • 04:00PM ET

5.54

Dollar change -0.42
Percentage change -7.05	%

Healthcare • Biotechnology • USA • NASD

KURA Kura Oncology Inc daily Stock Chart

Peers: AGIO BLUE FATE ADAP EXEL IOVA KPTI FGEN

| Held by: VTI IWM VXF XBI IWN IBB SCHA VTWO AVUV JSMD

Index	RUT	P/E	-	EPS (ttm)	-2.26	Insider Own	4.96%	Shs Outstand	86.80M	Perf Week	-7.97%
Market Cap	480.86M	Forward P/E	-	EPS next Y	-2.02	Insider Trans	-0.60%	Shs Float	82.49M	Perf Month	-12.89%
Enterprise Value	-130.40M	PEG	-	EPS next Q	-0.70	Inst Own	90.64%	Short Float	10.19%	Perf Quarter	-7.67%
Income	-197.17M	P/S	5.77	EPS this Y	4.99%	Inst Trans	3.07%	Short Ratio	6.59	Perf Half Y	-37.19%
Sales	83.28M	P/B	1.57	EPS next Y	-5.07%	ROA	-32.93%	Short Interest	8.41M	Perf YTD	-36.39%
Book/sh	3.52	P/C	0.76	EPS next 5Y	6.80%	ROE	-51.11%	52W High	21.57 -74.31%	Perf Year	-71.06%
Cash/sh	7.27	P/FCF	3.91	EPS past 3/5Y	-0.89% -6.05%	ROIC	-61.59%	52W Low	5.41 2.40%	Perf 3Y	-63.26%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	98.95%	Volatility	5.82% 5.06%	Perf 5Y	-67.28%
Dividend TTM	-	EV/Sales	-1.57	EPS Y/Y TTM	3.95%	Oper. Margin	-263.82%	ATR (14)	0.32	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.16	Sales Y/Y TTM	-	Profit Margin	-236.76%	RSI (14)	36.66	Recom	1.21
Dividend Gr. 3/5Y	- -	Current Ratio	6.16	EPS Q/Q	-28.65%	SMA20	-11.53%	Beta	0.17	Target Price	27.36
Payout	-	Debt/Eq	0.06	Sales Q/Q	-	SMA50	-10.58%	Rel Volume	2.69	Prev Close	5.96
Employees	192	LT Debt/Eq	0.05	Earnings	Aug 07 AMC	SMA200	-34.26%	Avg Volume	1.27M	Price	5.54
IPO	Sep 16, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-104.97% -64.17%	Trades		Volume	3,433,572	Change	-7.05%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-06-25	Downgrade	BTIG Research	Buy → Neutral
Oct-24-24	Initiated	UBS	Buy	$27
Oct-14-24	Downgrade	Stifel	Buy → Hold	$26 → $19
Dec-22-23	Initiated	Mizuho	Buy	$26
Aug-11-23	Initiated	BofA Securities	Buy	$31
Jul-27-23	Initiated	Scotiabank	Sector Perform	$10.50
May-17-23	Initiated	BTIG Research	Buy	$31
Jan-31-23	Initiated	Stifel	Buy	$25
Jul-12-22	Initiated	Cantor Fitzgerald	Overweight	$30
Feb-15-22	Initiated	Jefferies	Buy	$35
May-05-21	Resumed	Credit Suisse	Outperform	$42
Apr-26-21	Resumed	Credit Suisse	Outperform	$42
Dec-07-20	Reiterated	H.C. Wainwright	Buy	$40 → $45
Dec-03-20	Initiated	Stifel	Buy	$45
Nov-05-20	Downgrade	Piper Sandler	Overweight → Neutral
Jul-07-20	Initiated	Credit Suisse	Outperform	$27
May-05-20	Initiated	Barclays	Overweight	$24
Jul-18-19	Initiated	Deutsche Bank	Buy	$28
Nov-09-18	Initiated	Piper Jaffray	Overweight
Aug-01-18	Initiated	H.C. Wainwright	Buy	$31

Show Previous Ratings

Aug-07-25 06:15PM	Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -7.05%
05:16PM	Kura Oncology: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Kura Oncology Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-06-25 07:00AM	OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee (GlobeNewswire) -5.19%
Aug-04-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:30AM	Loading…
Jul-31-25 07:30AM	Kura Oncology to Report Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-03-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-12-25 08:48AM	Is the Options Market Predicting a Spike in Kura Oncology Stock? (Zacks)
07:30AM	Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress (GlobeNewswire)
Jun-10-25 08:08PM	Lightning Round: 'Wait and see situation' with Papa John's, says Jim Cramer (CNBC TV)
Jun-06-25 11:52AM	KURA Stock Rises More Than 15% This Past Week: Here's Why (Zacks)
07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-25 06:00PM	Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting (GlobeNewswire) +10.72%
Jun-01-25 07:00PM	Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML (GlobeNewswire)
May-22-25 05:30PM	Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting (GlobeNewswire) -9.62%
07:30AM	Loading…
May-20-25 07:30AM	Kura Oncology to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
May-14-25 10:00AM	Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress (GlobeNewswire)
May-06-25 07:30AM	Kura Oncology to Participate in Bank of America Securities Healthcare Conference (GlobeNewswire) -13.84%
May-02-25 10:51AM	Q1 2025 Kura Oncology Inc Earnings Call (Thomson Reuters StreetEvents)
07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
03:17AM	Kura Oncology Inc (KURA) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Rising Costs (GuruFocus.com)
May-01-25 08:48PM	Kura Oncology, Inc. (KURA) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:25PM	Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:26PM	Kura Oncology: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Kura Oncology Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-29-25 05:27AM	Kura doses first subjects in trial of ziftomenib for advanced GIST (Clinical Trials Arena)
Apr-28-25 07:30AM	Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST (GlobeNewswire)
Apr-24-25 07:30AM	Kura Oncology to Report First Quarter 2025 Financial Results (GlobeNewswire)
Apr-08-25 07:30AM	Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA (GlobeNewswire)
Apr-07-25 09:08AM	Syndax Pharmaceuticals: Down But Not Out (Seeking Alpha)
07:30AM	Loading…
Apr-04-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-01-25 07:30AM	Kura Oncology to Participate in Stifel Targeted Oncology Forum (GlobeNewswire)
Mar-26-25 07:30AM	Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting (GlobeNewswire)
Mar-07-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-25 11:19AM	Q4 2024 Kura Oncology Inc Earnings Call (Thomson Reuters StreetEvents)
02:24AM	Kura Oncology Inc (KURA) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Growth (GuruFocus.com)
Feb-26-25 05:35PM	Kura Oncology (KURA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:42PM	Kura Oncology: Q4 Earnings Snapshot (Associated Press Finance)
04:03PM	Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-25-25 07:30AM	Kura Oncology to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Feb-19-25 07:30AM	Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-07-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-05-25 04:01PM	Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs (GlobeNewswire)
Jan-06-25 04:30PM	Kura Oncology Announces Senior Executive Promotions (GlobeNewswire)
Dec-09-24 07:00AM	Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting (GlobeNewswire)
Dec-04-24 01:25PM	Why Is Kura Oncology, Inc. (KURA) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Dec-02-24 07:30AM	Kura Oncology to Host Virtual Investor Event on December 9, 2024 (GlobeNewswire)
Nov-25-24 07:30AM	Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-23-24 10:42AM	Kura Oncology, Inc. (KURA): Among the Most Promising Cancer Stocks According to Hedge Funds (Insider Monkey)
Nov-22-24 05:30AM	Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial (BioPharma Dive) +7.36%
Nov-21-24 04:15PM	Kura Crashes 37% After $1.53 Billion Deal Slams The Door On A Takeover (Investor's Business Daily) -36.77%
09:05AM	Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26% (Investor's Business Daily)
06:37AM	Kura Oncology partners Kyowa Kirin to advance AML treatment (Pharmaceutical Technology)
Nov-20-24 05:00PM	Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias (PR Newswire)
Nov-08-24 04:01PM	Kura Oncology Inc (KURA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising Expenses (GuruFocus.com)
Nov-07-24 05:15PM	Kura Oncology: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Kura Oncology Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-05-24 09:09AM	Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting (GlobeNewswire)
Oct-31-24 07:30AM	Kura Oncology to Report Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-29-24 08:00AM	Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors (Business Wire)
Oct-24-24 07:30AM	Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST) (GlobeNewswire)
Oct-23-24 07:30AM	Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors (GlobeNewswire)
Oct-09-24 05:54PM	Kura Oncology Inc (KURA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs (GuruFocus.com)
Sep-30-24 06:30PM	Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology (GlobeNewswire)
Sep-17-24 07:30AM	Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors (GlobeNewswire)
Sep-10-24 07:30AM	Kura Oncology to Participate in Cantor Global Healthcare Conference (GlobeNewswire)
Sep-05-24 12:01AM	Kura Oncology, Inc. (KURA): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-08-24 04:44PM	Kura Oncology: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Kura Oncology Reports Second Quarter 2024 Financial Results (GlobeNewswire)
07:30AM	Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST) (GlobeNewswire)
Aug-01-24 07:30AM	Kura Oncology to Report Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-05-24 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-24-24 07:30AM	Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes (GlobeNewswire)
Jun-17-24 09:00AM	Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies (GlobeNewswire)
Jun-07-24 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-24 07:30AM	Kura Oncology to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 11:44AM	Kura Oncology Enrolls 85 Patients in Ziftomenib Trial for Leukemia Drug (MT Newswires)
07:30AM	Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML (GlobeNewswire)
May-08-24 08:30AM	2 Incredible Growth Stocks to Buy Hand Over Fist (Motley Fool)
07:30AM	Kura Oncology to Participate in Bank of America Securities Healthcare Conference (GlobeNewswire)
May-06-24 10:14AM	Kura Oncology, Inc. (NASDAQ:KURA) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-03-24 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:03AM	Kura Oncology Inc (KURA) (Q1 2024) Earnings Call Transcript Highlights: Key Financial and ... (GuruFocus.com)
May-02-24 08:58PM	KURA Stock Earnings: Kura Oncology Misses EPS for Q1 2024 (InvestorPlace)
04:48PM	Kura Oncology: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Kura Oncology Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-25-24 07:30AM	Kura Oncology to Report First Quarter 2024 Financial Results (GlobeNewswire)
Apr-22-24 07:30AM	Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML (GlobeNewswire)
Apr-10-24 07:30AM	Kura Oncology to Participate in Stifel Targeted Oncology Forum (GlobeNewswire)
Apr-05-24 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-06-24 07:30AM	Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma (GlobeNewswire) +7.89%
Mar-01-24 05:00PM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-28-24 09:56AM	Kura Oncology, Inc. (NASDAQ:KURA) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:56AM	Q4 2023 Kura Oncology Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-24 04:44PM	Kura Oncology Inc (KURA) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
04:10PM	Kura Oncology: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-26-24 07:30AM	Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia (GlobeNewswire)
Feb-22-24 07:30AM	Kura Oncology to Participate in Three Upcoming Investor Conferences (GlobeNewswire)

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bair Teresa Brophy	Chief Legal Officer	May 19 '25	Sale	5.96	1,559	9,292	107,948	May 19 06:30 PM
FORD KATHLEEN	Chief Operating Officer	May 19 '25	Sale	6.28	1,558	9,777	21,367	May 19 06:30 PM
FORD KATHLEEN	Officer	May 19 '25	Proposed Sale	5.96	1,558	9,286		May 19 04:06 PM
Hasnain Faheem	Director	Mar 21 '25	Option Exercise	6.32	22,682	143,350	46,665	Mar 24 04:33 PM
Hasnain Faheem	Director	Mar 21 '25	Sale	8.00	22,682	181,456	23,983	Mar 24 04:33 PM
FAHEEM HASNAIN	Director	Mar 21 '25	Proposed Sale	7.85	30,000	235,500		Mar 21 04:21 PM
DOYLE THOMAS JAMES	SVP, Finance & Accounting	Jan 28 '25	Sale	7.87	4,949	38,958	88,193	Jan 28 08:54 PM
Leoni Mollie	Chief Medical Officer	Jan 28 '25	Sale	7.87	4,963	39,068	88,253	Jan 28 08:39 PM
Bair Teresa Brophy	Chief Legal Officer	Jan 28 '25	Sale	7.87	7,281	57,315	107,948	Jan 28 08:38 PM
FORD KATHLEEN	Chief Operating Officer	Jan 28 '25	Sale	7.87	1,817	14,303	21,367	Jan 28 08:38 PM
Burrows Francis	Chief Scientific Officer	Jan 28 '25	Sale	7.87	2,166	17,051	20,705	Jan 28 08:38 PM
Powl Brian T.	Chief Commercial Officer	Jan 28 '25	Sale	7.87	1,583	12,461	59,667	Jan 28 08:38 PM
LEONI MOLLIE	Officer	Jan 28 '25	Proposed Sale	7.77	4,963	38,563		Jan 28 08:37 PM
BAIR TERESA BROPHY	Officer	Jan 28 '25	Proposed Sale	7.77	7,281	56,573		Jan 28 08:37 PM
FORD KATHLEEN	Officer	Jan 28 '25	Proposed Sale	7.77	1,817	14,118		Jan 28 08:37 PM
DOYLE THOMAS JAMES	Officer	Jan 28 '25	Proposed Sale	7.77	4,949	38,454		Jan 28 08:37 PM
BURROWS FRANCIS	Officer	Jan 28 '25	Proposed Sale	7.77	2,166	16,830		Jan 28 08:37 PM
POWL BRIAN T	Officer	Jan 28 '25	Proposed Sale	7.77	1,583	12,300		Jan 28 08:36 PM
FORD KATHLEEN	Chief Operating Officer	Nov 18 '24	Sale	16.03	526	8,434	23,184	Nov 19 04:05 PM
FORD KATHLEEN	Officer	Nov 18 '24	Proposed Sale	15.99	526	8,410		Nov 18 04:03 PM

RNA

Avidity Biosciences Inc

PBYI

Puma Biotechnology Inc

KURA

Kura Oncology Inc

Upgrade your FINVIZ experience